3 Boomerang Closes Third Tuck-in Acquisition, Accelerating Development into Scaled Life Sciences Advisory Platform

3 Boomerang 完成第三次收购，加速发展成为规模化生命科学咨询平台

FISHERS, Ind. and ROYERSFORD, Pa.

印第安纳州费希尔和宾夕法尼亚州罗耶斯福德

,

，

April 30, 2026

2026年4月30日

/PRNewswire/ --

/PRNewswire/ --

Pinnaql, Inc.

皮纳克尔公司

, ('Pinnaql' or the 'Company'), a

，（“Pinnaql”或“公司”），一家

3 Boomerang Capital, LP

3回旋镖资本，LP

('3BC') portfolio company, today announced it has acquired Pharma Resource Group, Inc. ('PRG'), a leading provider of analytical sciences, formulation, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. The closing marks the third tuck-in acquisition Pinnaql has completed in the past 10 months..

('3BC') 投资组合公司今日宣布，已完成对 Pharma Resource Group, Inc. ('PRG') 的收购。PRG 是一家领先的分析科学、配方、科学写作、制造及变更控制咨询服务供应商，服务于制药和生命科学行业。此次收购标志着 Pinnaql 在过去10个月内完成的第三笔补充型收购。

'The addition of PRG marks another major step in building Pinnaql into the partner life sciences companies can rely on, from development to commercial readiness,' said John Duffin, Chief Executive Officer of Pinnaql. 'By combining PRG's scientific development and scale-up expertise with our established strengths in validation, engineering, quality systems, and regulatory compliance, we can now support clients throughout their full spectrum of growth.

“增加PRG标志着将Pinnaql打造成生命科学公司可信赖的合作伙伴的又一重要步骤，从开发到商业准备皆是如此，”Pinnaql首席执行官约翰·达芬表示。“通过将PRG在科学开发和规模扩大方面的专业知识与我们在验证、工程、质量体系和法规合规方面的优势相结合，我们现在可以支持客户在其整个增长过程中。”

From laboratory innovation to manufacturing readiness, we help organizations reduce execution risk, avoid compliance setbacks, and bring therapies to market with greater speed and confidence.'.

从实验室创新到生产准备，我们帮助组织降低执行风险，避免合规挫折，并以更快的速度和信心将疗法推向市场。

Founded in 2007, PRG has built long-standing relationships with pharmaceutical clients by delivering specialized support across formulation and manufacturing processes. Its capabilities complement Pinnaql's existing focus on engineering, regulation, validation, and quality systems, creating a more comprehensive offering for customers at every stage of the product lifecycle..

成立于 2007 年的 PRG 通过在配方和生产工艺方面提供专门支持，与制药客户建立了长期的关系。其能力与 Pinnaql 现有的工程、法规、验证和质量体系重点相辅相成，为产品生命周期每个阶段的客户创造了更全面的服务 offering。

The PRG acquisition builds on Pinnaql's strategy to establish a scaled, multi-disciplinary platform serving the evolving needs of life sciences companies. Following its two prior acquisitions, including

PRG的收购建立在Pinnaql的战略基础上，旨在打造一个规模化的、多学科的平台，以满足生命科学公司不断变化的需求。在此之前的两次收购中，包括

Validation & Engineering Group, Inc.

验证与工程集团，股份有限公司

, Pinnaql continues to expand its profile in the areas of compliance, quality, and technical consulting services.

，Pinnaql继续在合规、质量和专业技术咨询服务领域拓展其业务范围。

'We are pleased to support Pinnaql's ongoing growth through strategic acquisitions that expand its capabilities and market reach,' said Peter Wen, Principal at 3 Boomerang Capital. 'PRG enhances the platform's technical depth and further positions Pinnaql as a differentiated partner to life sciences organizations.'.

“我们很高兴通过战略性收购来支持Pinnaql的持续增长，这将扩展其能力和市场覆盖范围，”3 Boomerang Capital的负责人Peter Wen表示。“PRG增强了该平台的技术深度，并进一步巩固了Pinnaql作为生命科学组织差异化合作伙伴的地位。”

About Pinnaql

关于Pinnaql

Pinnaql (an LSOMS Holdings company) provides quality, regulatory, and operational excellence consulting to biopharmaceutical, medical device, and CDMO companies worldwide. The company's mission is to deliver expert-driven, compliant solutions that empower clients to accelerate innovation and improve human health.

Pinnaql（一家LSOMS Holdings公司）为全球的生物制药、医疗器械和CDMO公司提供质量、法规和运营卓越性咨询服务。公司的使命是提供专家驱动的、合规的解决方案，帮助客户加速创新并改善人类健康。

Pinnaql supports life sciences organizations by ensuring operational readiness, reducing the risk of regulatory setbacks, and enabling clients to stay focused on advancing science, supporting patients, and bringing new therapies to market. As a trusted partner, Pinnaql elevates compliance and empowers innovation throughout the product lifecycle. .

Pinnaql 通过确保运营准备、降低监管挫折的风险，帮助生命科学组织专注于推进科学、支持患者并推动新疗法上市。作为值得信赖的合作伙伴，Pinnaql 在整个产品生命周期中提升合规性并推动创新。

For more information, visit

欲了解更多信息，请访问

https://www.pinnaql.com

https://www.pinnaql.com

.

。

About 3 Boomerang Capital

关于3号回旋镖资本

3 Boomerang Capital, L.P. is a lower-middle-market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs across North America and Western Europe. 3BC's areas of investment focus span four key healthcare sectors: biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care.

3 Boomerang Capital, L.P. 是一家专注于中低端市场医疗保健的私募股权公司，致力于与北美和西欧的医疗保健企业家建立创新的投资合作关系。3BC 的投资重点领域涵盖四大关键医疗保健领域：生物制药外包、医疗器械和诊断制造、信息技术和科技赋能服务，以及替代站点护理。

The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights.

该公司专注于支持由创始人领导的企业，提供在医疗保健市场中实现成功增长和创新所需的指导和资源。通过战略性地集中于四个核心领域，3 Boomerang Capital 有能力实现其赋能医疗创业者、推动医疗企业达到新高度的使命。

The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a $376 million investment vehicle. To learn more, please visit .

该公司目前正在通过其旗舰基金 3 Boomerang Capital I, LP 进行投资，这是一只规模达 3.76 亿美元的投资工具。欲了解更多信息，请访问 。

https://www.3boomerang.com/

https://www.3boomerang.com/

.

。

Media Contact: Laura Simpson, JConnelly for 3 Boomerang Capital,

媒体联系人：劳拉·辛普森，JConnelly 代表 3 Boomerang Capital，

[email protected]

电子邮件地址

SOURCE 3 Boomerang Capital

来源 3 回旋资本

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示